Search - tctmd.com

Displaying 181 - 200 of 665

Sort: Relevancy | Date

Presentation TCT 2017

Viewpoint #2: Not So Fast! GARY and Other Studies Indicate an Important Role for Surgery in Intermediate-risk Patients

Presenter: Thomas Walther

October 30, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

Presentation TCT 2017

Featured Lecture: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients : Complete 1-Year Outcomes from the SURTAVI Trial

Presenter: Martin B. Leon, Patrick T. O'Gara, Nicolas M. Van Mieghem

October 30, 2017

Presentation TCT 2017

Insights From the New 2017 ESC Valve Disease Guidelines: Changes in the Management of Aortic Stenosis

Presenter: Martin B. Leon, Patrick T. O'Gara, Olaf Wendler

October 30, 2017

Presentation TCT 2017

Take-home Messages for Managing Aortic Valve Disease From the 2017 AHA/ACC Focused Update

Presenter: Martin B. Leon, Patrick T. O'Gara, Allan Schwartz

October 30, 2017

Presentation TCT 2017

Futuristic and Novel #2: Using Artificial Intelligence (Machine Learning) to Direct Acquisition and Interpretation of Echocardiograms Improving Access and Quality of Valve Disease Diagnosis

Presenter: Robert O. Bonow, Michael J. Mack, Randolph P. Martin

October 30, 2017

Presentation TCT 2017

Futuristic and Novel #1: The Promise of Tissue Engineered Bioprosthetic Heart Valves (Both Surgical and Transcatheter) is Within Reach

Presenter: Robert O. Bonow, Michael J. Mack, Maximilian Y Emmert

October 30, 2017

Presentation TCT 2017

From Traditional Society Guidelines to Rapid Communications (e.g. BMJ WikiRecs): Evidence Development, Clinical Practice Standards, and Treatment Recommendations

Presenter: Robert O. Bonow, Michael J. Mack, David Hildick-Smith

October 30, 2017

Presentation TCT 2017

Aortic Stenosis Population Oddities Who are the Patients Not Being Diagnosed or Treated?

Presenter: Robert O. Bonow, Michael J. Mack, Maurice E. Sarano

October 30, 2017

Presentation TCT 2017

Counterpoint Access to Modern Valve Therapies for Underserved Populations Trumps Arbitrary Guidelines Favoring High-Volume Urban Centers!

Presenter: Uzoma Ibebuogu

October 30, 2017

Presentation TCT 2017

Point A Tiered Centers of Excellence Approach Makes Sense!

Presenter: Patrick T. O'Gara

October 30, 2017

Presentation TCT 2017

Counterpoint In the Modern Era, Crowd Wisdom, Cumulative Experience and New Technology Trumps Case Volume!

Presenter: Martin B. Leon

October 30, 2017

Presentation TCT 2017

Point - Clearly, The More You Do, The Better You Are!

Presenter: John D. Carroll

October 30, 2017

Presentation TCT 2017

Featured Lecture: The Vancouver Multidisciplinary, Multimodality, but Minimalist Clinical Pathway Facilitates Safe Next Day Discharge Home at Low, Medium, and High Volume Transcatheter Aortic Valve Replacement Centres: the 3M TAVR Study

Presenter: Robert O. Bonow, Michael J. Mack, David A. Wood

October 30, 2017

Presentation TCT 2017

Staging Classification of Aortic Stenosis Based Upon the Extent of Cardiac Damage A Novel Concept

Presenter: Robert O. Bonow, Michael J. Mack, Philippe Genereux

October 30, 2017

Presentation TCT 2017

Refining the Classic Definition of Aortic Stenosis: A Dynamic Interpretation Including the Role of Ventricular Stroke Work and Vascular Impedance

Presenter: Robert O. Bonow, Michael J. Mack, Elazer R. Edelman

October 30, 2017

Presentation TCT 2017

Keynote Lecture. European Commission: Evolving Impact of Device Regulation in Europe

Presenter: Gregg W. Stone, Bram D. Zuckerman, Alan G. Fraser

October 30, 2017

Presentation TCT 2017

Keynote Lecture - FDA/CDRH: Evolving Impact of Device Regulation in the US

Presenter: Gregg W. Stone, Bram D. Zuckerman, William H. Maisel

October 30, 2017

Presentation TCT 2017

The Impact of Regulation on Forty Years of PCI and 15 years of TAVR: Industry Perspectives

Presenter: Gregg W. Stone, Bram D. Zuckerman, Richard E. Kuntz

October 30, 2017

Presentation TCT 2017

The Impact of Regulation on Forty Years of PCI and 15 years of TAVR: Physician-Scientist Perspectives

Presenter: Gregg W. Stone, Bram D. Zuckerman

October 30, 2017

Advertisement

Viewpoint #2: Not So Fast! GARY and Other Studies Indicate an Important Role for Surgery in Intermediate-risk Patients

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Featured Lecture: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients : Complete 1-Year Outcomes from the SURTAVI Trial

Insights From the New 2017 ESC Valve Disease Guidelines: Changes in the Management of Aortic Stenosis

Take-home Messages for Managing Aortic Valve Disease From the 2017 AHA/ACC Focused Update

Futuristic and Novel #2: Using Artificial Intelligence (Machine Learning) to Direct Acquisition and Interpretation of Echocardiograms Improving Access and Quality of Valve Disease Diagnosis

Futuristic and Novel #1: The Promise of Tissue Engineered Bioprosthetic Heart Valves (Both Surgical and Transcatheter) is Within Reach

From Traditional Society Guidelines to Rapid Communications (e.g. BMJ WikiRecs): Evidence Development, Clinical Practice Standards, and Treatment Recommendations

Aortic Stenosis Population Oddities Who are the Patients Not Being Diagnosed or Treated?

Counterpoint Access to Modern Valve Therapies for Underserved Populations Trumps Arbitrary Guidelines Favoring High-Volume Urban Centers!

Point A Tiered Centers of Excellence Approach Makes Sense!

Counterpoint In the Modern Era, Crowd Wisdom, Cumulative Experience and New Technology Trumps Case Volume!

Point - Clearly, The More You Do, The Better You Are!

Featured Lecture: The Vancouver Multidisciplinary, Multimodality, but Minimalist Clinical Pathway Facilitates Safe Next Day Discharge Home at Low, Medium, and High Volume Transcatheter Aortic Valve Replacement Centres: the 3M TAVR Study

Staging Classification of Aortic Stenosis Based Upon the Extent of Cardiac Damage A Novel Concept

Refining the Classic Definition of Aortic Stenosis: A Dynamic Interpretation Including the Role of Ventricular Stroke Work and Vascular Impedance

Keynote Lecture. European Commission: Evolving Impact of Device Regulation in Europe

Keynote Lecture - FDA/CDRH: Evolving Impact of Device Regulation in the US

The Impact of Regulation on Forty Years of PCI and 15 years of TAVR: Industry Perspectives

The Impact of Regulation on Forty Years of PCI and 15 years of TAVR: Physician-Scientist Perspectives

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content